Background: The function of the immune system in prostate cancer (PC)
might promote carcinogenesis. PC is a common cancer in men. Regulatory
B cells (Bregs) are a new subtype of B cells that have suppressive
roles in the immune system. Interleukin-10 (IL-10) is a dominant
mediator of immune suppression released by Bregs. Objective: The
purpose of this research was to examine the frequency of CD19+IL10+ B
cells and IL-10 mRNA expression in patients with PC compared to
patients with benign prostatic hyperplasia (BPH). Methods: Forty
paraffin tissue samples from patients with PC and 32 paraffin tissue
samples from patients with BPH were entered in this study. The
immunohistochemistry staining was used to evaluate the pattern
expression of CD19 and IL-10 markers. IL-10 mRNA expression in fresh
tissue was determined by real time-polymerase chain reaction (RT-PCR).
Results: The frequency of CD19+IL-10+ B cells and IL-10 mRNA expression
in PC patients were significantly higher than patients with BPH. Also,
there was no meaningful relationship between the frequency of
IL-10+CD19+ B cells and gleason scores in patients with PC.
Conclusions: Our findings suggested that frequency of IL-10+CD19+ B
cells correlates with progressive stage of PC